Paradigm Biopharmaceuticals is currently conducting a global, Phase 3 clinical trial for its iPPS treatment for osteoarthritis (OA).
In this interview, Paradigm Biopharmaceuticals Managing Director Paul Rennie discusses the potential for the company’s breakthrough treatment to break into the $8.28 billion global market for osteoarthritis therapeutics.
Paradigm has cashed up, having raised $30.1 million in October last year to develop its iPPS treatment for the disease.